Immunocore Holdings plc Revenue From Contracts With Customers
Immunocore Holdings plc (IMCR) reported Revenue From Contracts With Customers of GBP 45.51 million for the 3-month period ending 2023-06-30, per its 6-K filed 2023-08-10.
Discontinued › Income Statement › Other Income
ifrs-full:RevenueFromContractsWithCustomers · last filed 2023-08-10
- Immunocore Holdings plc revenue from contracts with customers for the quarter ending 2023-06-30 was 45.51M GBP, a 64.31% increase year-over-year.
- Immunocore Holdings plc revenue from contracts with customers for the quarter ending 2022-12-31 was 42.30M GBP, a 1567.78% increase year-over-year.
- Immunocore Holdings plc revenue from contracts with customers for the quarter ending 2022-09-30 was 36.30M GBP, a 7558.86% increase year-over-year.
- Immunocore Holdings plc revenue from contracts with customers for the quarter ending 2022-06-30 was 27.70M GBP.
| Period end | Revenue From Contracts With Customers 3 month | Revenue From Contracts With Customers 6 month | Revenue From Contracts With Customers 9 month | Revenue From Contracts With Customers 12 month | Revenue From Contracts With Customers 12 month as first filed |
|---|---|---|---|---|---|
| 2023-06-30 | 45.51M GBP 6-K · filed 2023-08-10 | 87.57M GBP 6-K · filed 2023-08-10 | |||
| 2022-12-31 | 42.30M GBP derived: 20-F 12 month − 6-K/A 9 month · filed 2023-03-01 | 78.60M GBP derived: sum of 2 quarters · filed 2023-03-01 | 106.30M GBP derived: sum of 3 quarters · filed 2023-08-10 | 116.81M GBP 20-F · filed 2023-03-01 | |
| 2022-09-30 | 36.30M GBP 6-K/A · filed 2022-11-18 | 64.00M GBP derived: sum of 2 quarters · filed 2023-08-10 | 74.51M GBP 6-K/A · filed 2022-11-18 | ||
| 2022-06-30 | 27.70M GBP 6-K · filed 2023-08-10 | 38.21M GBP 6-K · filed 2023-08-10 | |||
| 2021-12-31 | 2.54M GBP derived: 20-F 12 month − 6-K/A 9 month · filed 2023-03-01 | 3.01M GBP derived: sum of 2 quarters · filed 2023-03-01 | 3.01M GBP 20-F · filed 2023-03-01 | 26.52M GBP 20-F · filed 2022-03-03 | |
| 2021-09-30 | 474.00K GBP 6-K/A · filed 2022-11-18 | 474.00K GBP 6-K/A · filed 2022-11-18 | |||
| 2020-12-31 | 0.00 GBP 20-F · filed 2023-03-01 | 30.11M GBP 20-F · filed 2021-03-25 | |||
| 2019-12-31 | 25.67M GBP 20-F · filed 2022-03-03 | ||||
| 2018-12-31 | 23.65M GBP 20-F · filed 2021-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |